{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-043290","form_type":"8-K","ticker":"CCCC","cik":"0001662579","company_name":"C4 Therapeutics, Inc.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.071691+00:00","generated_at":"2026-05-17T05:06:13.513872+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"C4 Therapeutics Enters Clinical Trial Collaboration with Pfizer for Multiple Myeloma Drug Combination","bullets":["C4 Therapeutics and Pfizer signed a clinical trial collaboration and supply agreement for elranatamab and cemsidomide.","Pfizer will supply elranatamab (ELREXFIO) at no cost for a Phase 1b trial in relapsed/refractory multiple myeloma.","The Phase 1b trial will evaluate cemsidomide, dexamethasone, and elranatamab as second-line or later therapy.","Trial expected to start in Q2 2026; C4 Therapeutics sponsors and conducts the trial.","C4 Therapeutics CEO noted potential to improve outcomes and combine with a growing standard-of-care bispecific."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-043290","json":"https://secwatch.observer/filing/0001628280-25-043290.json","markdown":"https://secwatch.observer/filing/0001628280-25-043290.md","text":"https://secwatch.observer/filing/0001628280-25-043290.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025043290/0001628280-25-043290-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662579/000162828025043290/cccc-20251001.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T05:06:13.513872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}